Naprius (Naproxen)

Naproxen works by reversibly inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for prostaglandin synthesis. By reducing prostaglandin production, it decreases inflammation, pain, and fever at the site where the topical product is applied.

The appropriate dose of Naprius is determined by the prescribing healthcare professional based on the patient’s condition, severity of symptoms, and treatment guidelines. Patients should follow the prescriber’s instructions and the product label for application frequency and amount.

Safety of topical naproxen in pregnancy or while breastfeeding has not been fully established. Healthcare providers generally advise caution and may recommend alternative therapies, especially during the first trimester or if the infant is nursing, to avoid potential risks.

To order Naprius, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naprius contains naproxen, which offers a longer half‑life than some other topical NSAIDs such as diclofenac. This may allow less frequent application while providing comparable anti‑inflammatory and analgesic effects. Choice of product often depends on physician preference, patient tolerance and specific formulation characteristics.

Naprius should be stored at ambient temperature, ideally below 25 °C. Keep the container tightly closed, protect it from moisture, direct sunlight and excessive heat. Do not freeze the product, and keep it out of reach of children.

Apply a thin layer of Naprius to clean, dry skin over the affected area, gently rubbing it in until fully absorbed. Follow the prescriber’s recommended frequency, typically 2‑3 times daily, and avoid covering the area with occlusive dressings unless instructed.

Serious risks include severe allergic reactions such as Stevens‑Johnson syndrome, systemic NSAID effects like gastrointestinal bleeding, renal impairment, and cardiovascular events. Patients should seek immediate medical attention if they experience signs of a serious reaction, such as widespread rash, difficulty breathing, or unexplained bruising.

Naprius should not be used by individuals with known hypersensitivity to naproxen, other NSAIDs, or any component of the formulation. It is also contraindicated in patients with active gastrointestinal ulcers, severe renal or hepatic impairment, and those on anticoagulant therapy unless specifically advised by a physician.